Every material Form 8-K Scribe Therapeutics, Inc. has filed with the SEC since September 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Scribe Therapeutics reported second quarter 2026 results for the period ended June 30, 2026. Net loss narrowed to $6.5 million from $9.9 million a year earlier, but collaboration revenue fell to $1.9 million from $4.9 million. The company said its July 2026 IPO and concurrent Sanofi private placement, with about $140.6 million of net proceeds, extend its funding into the first half of 2029.
Net loss of $6.5 million, or $2.62 per share, versus $9.9 million, or $4.08 per share, a year earlier
Collaboration revenue of $1.9 million versus $4.9 million; research and development expenses of $8.8 million versus $13.9 million
Cash, cash equivalents and marketable securities of $43.0 million at June 30, 2026, plus about $140.6 million of net IPO and private placement proceeds
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Scribe Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →